Graham Goodrich
Chief Commercial Officer
Apnimed
Bio:
Graham Goodrich has more than 20 years of experience commercializing novel treatments in neurology, respiratory, immunology, and cardiometabolic health, including brands such as Nurtec, Jardiance, Spiriva and Gardasil. He is a self-proclaimed, “paradigm-shift junkie” drawn to categories that are on the brink of transformation.
Presently, Graham serves as the Chief Commercial Officer at Apnimed, a biotech based in Cambridge, MA that is dedicated to the discovery, development, and commercialization of novel oral medications for the treatment of sleep-related breathing diseases.
They are preparing their first NDA for FDA submission with a goal of launching the first-ever oral pill to treat obstructive sleep apnea in Q1, 2027.